Loading market data...
Wed, 21 Oct 2026
11:59:44 am
Wed, 21 Oct 2026
11:59:44 am
Synopsis
Gland Pharma, Tata Technologies and Nexus Select Trust remain in focus as major investors and shareholders make significant market transactions.
Gland Pharma shares closed 0.84% higher at ₹2,932.40 on September 4, after promoter Fosun Pharma sold a 4.5% stake in the pharmaceutical company through block deals worth around ₹2,121 crore.
Fosun Pharma Industrial, a wholly owned subsidiary of Shanghai Fosun Pharmaceutical, sold 75.05 lakh shares at ₹2,826.60 per share. The shares were acquired by 11 institutional investors.
The transaction represented around 4.5% of Gland Pharma's equity. Kotak Mahindra Mutual Fund was the biggest buyer, acquiring 27.93 lakh shares, representing a 1.69% stake, for around ₹789.5 crore.
Axis Mutual Fund bought 13.57 lakh shares for ₹383.6 crore, while ICICI Prudential AMC purchased 10.39 lakh shares for ₹293.68 crore. Other buyers included Aditya Birla Sun Life AMC, SBI Life Insurance, HDFC Standard Life Insurance, Mirae Asset Mutual Fund, Societe Generale, Kotak Mahindra Life Insurance and Sundaram Mutual Fund.
Gland Pharma shares rose 0.84% to ₹2,932.40 on September 4 despite the large promoter stake sale. The stock closed at its highest level since August 14, according to the supplied market data.
The transaction comes after reports that Fosun Pharma was looking to reduce its holding in Gland Pharma. The promoter held 51.77% in the company as of June 2026 before the reported sale.
Former Tata Technologies CEO Patrick Raymon McGoldrick sold 21 lakh shares of the engineering services company, representing a 0.51% stake, for ₹164.85 crore.
The shares were sold at ₹785 per share and were acquired by ICICI Prudential AMC, Kotak Mahindra AMC, 360 ONE Asset Management and Carnelian Asset Management & Advisors.
Tata Technologies shares fell 0.63% to ₹800 on September 4 and declined 4.12% during the week.
WhiteOak Capital Mutual Fund bought 74.95 lakh units of Nexus Select Trust from Blackstone owned BREP Asia SG Forum Holding for ₹122.92 crore.
The transaction took place at ₹164 per unit. Nexus Select Trust units closed at ₹165.89, down 1.14% on September 4.
The major block deals show continued institutional activity across pharmaceutical, technology and real estate related securities. Investors will track further changes in promoter holdings and institutional ownership in the coming sessions.
Gland Pharma is worth watching because the stake sale brought major institutional buyers into the stock while the shares also closed higher on September 4.
The Fosun Pharma stake sale alone does not determine whether Gland Pharma is a good buy. Investors should also assess its earnings, valuation and business outlook.
Gland Pharma shares closed higher on September 4 despite the promoter stake sale. The stock ended at ₹2,932.40.
Gland Pharma closed at ₹2,932.40 on September 4, 2026, according to the supplied market data.
Gland Pharma could interest long term investors looking at the pharmaceutical sector, but its future performance will depend on earnings growth, product demand and valuation.
The sale changes the company's shareholder structure, while institutional investors bought the shares. The transaction itself does not confirm whether the development is positive or negative for Gland Pharma.
Fosun Pharma sold a 4.5% stake through a block deal, but the specific reason for the sale was not disclosed in the supplied information.
Fosun Pharma Industrial sold 75.05 lakh Gland Pharma shares, representing a 4.5% stake in the company.
The Fosun Pharma transaction was worth around ₹2,121.5 crore at ₹2,826.60 per share.
The Gland Pharma shares sold by Fosun Pharma were acquired at ₹2,826.60 per share.
Kotak Mahindra Mutual Fund was the largest buyer in the transaction, but institutional buying alone does not guarantee future gains in Gland Pharma.
Kotak Mahindra Mutual Fund bought around 27.93 lakh Gland Pharma shares, representing about a 1.69% stake.
Axis Mutual Fund bought a sizeable stake in the block deal. This shows institutional participation, but investors should also assess Gland Pharma's fundamentals.
Axis Mutual Fund bought around 13.57 lakh Gland Pharma shares for about ₹383.6 crore.
ICICI Prudential AMC was among the major institutional buyers of Gland Pharma shares. The purchase increases institutional participation in the stock.
ICICI Prudential AMC bought around 10.39 lakh Gland Pharma shares for about ₹293.68 crore.
The shares were bought by 11 institutional investors, including Kotak Mahindra Mutual Fund, Axis Mutual Fund and ICICI Prudential AMC.
A promoter stake sale can attract attention, but it does not automatically mean that the company's business outlook has weakened. The reason for the sale and the resulting ownership structure matter.
Fosun Pharma held 51.77% of Gland Pharma as of June 2026 before the reported sale. The 4.5% transaction would reduce that holding if no other changes occurred.
Fosun Pharma remained the largest shareholder based on the June 2026 holding data. Its exact post transaction holding should be checked against the latest exchange disclosure.
Gland Pharma is a major pharmaceutical company focused on generic injectable products. Investors should compare its earnings, valuation and growth with other pharma companies before deciding.
Gland Pharma may suit investors seeking pharmaceutical sector exposure, but long term returns will depend on business performance, margins, product approvals and valuation.
The participation of several large institutional investors can increase market interest, but a block deal alone does not confirm a bullish trend.
Investors should not base a buy decision only on the block deal. Gland Pharma's financial performance, valuation and future business prospects also need to be considered.
Institutional buying can increase confidence and liquidity, but it does not change the company's operating fundamentals by itself.
Gland Pharma shares closed 0.84% higher at ₹2,932.40 on September 4 despite the large promoter transaction.
Gland Pharma attracted the largest transaction highlighted in this news, but there is no single best stock based only on block deal activity.
Tata Technologies remains worth watching after former CEO Patrick McGoldrick sold part of his holding. Investors should also consider its earnings, valuation and business outlook.
Patrick McGoldrick sold 21 lakh Tata Technologies shares, but the specific reason for his sale was not disclosed in the supplied information.
McGoldrick sold 21 lakh shares, representing a 0.51% stake in Tata Technologies.
Tata Technologies could interest investors seeking exposure to engineering and digital services, but its long term performance will depend on revenue growth, profitability and valuation.
Yes. ICICI Prudential Mutual Fund, Kotak Mahindra Mutual Fund, 360 ONE Asset Management and Carnelian Asset Management & Advisors bought the shares sold by McGoldrick.
Nexus Select Trust is worth watching after WhiteOak Capital Mutual Fund bought units, but investors should assess rental income, distributions, valuation and the broader real estate market.
Yes. WhiteOak Capital Mutual Fund bought 74.95 lakh Nexus Select Trust units at ₹164 per unit.
The purchase shows institutional interest in Nexus Select Trust, but one transaction does not determine the future performance of the trust.
The September 4 transactions included the Fosun Pharma sale in Gland Pharma, the Patrick McGoldrick sale in Tata Technologies and WhiteOak Capital's purchase of Nexus Select Trust units.
Block deals can increase investor attention and reveal large institutional or shareholder transactions, but they do not guarantee that a stock will rise.
Not necessarily. Investors should examine why the transaction occurred, the company's fundamentals, valuation and the broader market before making a decision.
Financial journalist specializing in market analysis, stock research, and investment trends. Dedicated to providing accurate, timely insights for informed decision-making.
Credentials: Experienced financial journalist with expertise in equity markets and economic analysis
The information provided in this article is for educational and informational purposes only and should not be construed as financial, investment, or legal advice. welomoney does not provide personalized investment recommendations.
For detailed terms and conditions, please read our Disclaimer and Terms of Service.
Indian IT stocks rose 2.6% as LTTS shares jumped 15% after Q2 FY27 results. Jefferies sees scope for a valuation re-rating across the sector.
Diwali Muhurat Trading 2026 is scheduled for November 8 from 2:20 PM to 3:30 PM. See NSE and BSE timings, pre-open session and market schedule.
Sugar stocks fell up to 5.79% after the government barred sugarcane juice and syrup for FY27 ethanol procurement. Analysts flag earnings pressure.
NSE indices on October 16, 2026: Nifty IT rises 3.12%, Nifty 50 gains 0.49%, while Nifty FMCG, Capital Market and Bank indices decline.
India-US trade deal could influence Sensex, Nifty 50 and export stocks. Explore five sectors to watch and the key factors investors should track.
